Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Increlex in Autism Spectrum Disorder
NCT01970345Phase 2Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- May 2014
- Primary completion
- Sep 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of mecasermin in Autism Spectrum Disorder (ASD), sponsored by Icahn School of Medicine at Mount Sinai. Started May 2014; status: terminated.
02
Drugs
mecasermin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01970345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01970345.